scholarly journals Retrospective Analysis of Clinicopathological Features and Familial Cancer History of Synchronous Bilateral Breast Cancer

Healthcare ◽  
2021 ◽  
Vol 9 (9) ◽  
pp. 1203
Author(s):  
Kai-Ling Huang ◽  
Yu-Ling Liu ◽  
Ya-Ying Hsu ◽  
Wen-Ling Kuo
Keyword(s):  
Breast Cancer ◽  
Strong Predictor ◽  
Familial Cancer ◽  
Parp Inhibitor ◽  
Breast Cancer Incidence ◽  
Bilateral Breast Cancer ◽  
Population Based ◽  
Clinicopathological Features ◽  
Cancer History ◽  
Synchronous Bilateral Breast Cancer

Bilateral breast cancer is a strong predictor of BRCA 1/2 mutation and hence one criterion indicated for hereditary genetic testing. The purpose of this study is to assess the characteristics of synchronous bilateral breast cancer (SBBC) and its association with personal and familial cancer traits. Patients diagnosed with SBBC in our institute between 1992 and 2018 were retrospectively reviewed, and the information of clinicopathological features, personal and family cancer history were analyzed. Of the 307 SBBCs enrolled, the growing case number generally aligned with the regional breast cancer incidence after the era of population-based mammography screening. SBBC patients had similar cancer stages but worse survival outcomes than those in the standard scenario. A total of 42.0% had mixed pathological diagnoses, and 22.8% had discordant immunohistochemistry (IHC) subtypes from both sides, which contributed to treatment challenges. The correlation of SBBC with hereditary breast and ovarian cancer (HBOC) syndrome was strongly implied, as 20.7% of our SBBC patients with known familial cancer histories had HOBC-related familial cancers (breast, ovarian, or prostate cancers). These findings highlight the need for genetic counseling and germline mutation testing in patients with SBBC. Early PARP inhibitor treatment should also be considered in high-risk cases for outcome improvement.

National trends of synchronous bilateral breast cancer incidence in the United States

2019 ◽  
Vol 178 (1) ◽  
pp. 161-167 ◽  
Author(s):  
Takehiko Sakai ◽  
Enver Ozkurt ◽  
Stephen DeSantis ◽  
Stephanie M. Wong ◽  
Laurel Rosenbaum ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Bilateral Breast Cancer ◽  
The United States ◽  
Synchronous Bilateral Breast Cancer ◽  
National Trends

scholarly journals Quantitative and dosimetric analysis for treating synchronous bilateral breast cancer using two radiotherapy planning techniques

2021 ◽  
Vol 27 (3) ◽  
pp. 201-206
Author(s):  
Özlem Mermut ◽  
Aysun Ozsoy Ata ◽  
Didem Can Trabulus
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Organs At Risk ◽  
Bilateral Breast Cancer ◽  
Radiotherapy Planning ◽  
Conformity Index ◽  
Treatment Unit ◽  
Significant Difference ◽  
Synchronous Bilateral Breast Cancer ◽  
The Right

Abstract Objective: We compared mono-isocenter and dual-isocenter plans in synchronous bilateral breast cancer (SBBC), which is defined as tumours occurring simultaneously in both breasts, and evaluated the effects of these differences in plans on organs-at-risk (OARs). Materials and methods: We evaluated 10 women with early stage, nod negative (Tis-2N0M0) SBBC. The treatment dose was determined to be 50 Gy. We used mean dose and VXGy to evaluate the OARs. To evaluate the effectiveness of treatment plans, Homogeneity index (HI), conformity index (CI) and sigma index (SI) and monitor units (MU) of monoisocenter (MIT) and dual-isocenter (DIT) plans were compared. During bilateral breast planning, for the single-centre plan, the isocenter was placed at the center of both breasts at a depth of 3-4 cm. For the two-center plan, dual-isocenters were placed on the right and left breasts. Results: No significant difference between the techniques in terms of the scope of the target volume was observed. Statistically significant results were not achieved in MIT and DIT plans for OARs. Upon comparing MIT and DIT, the right-side monitor unit (MU) value in DIT (p = 0.011) was statistically significantly lower than that in MIT. Upon comparing right-left side MIT and DIT, the MU value (p = 0.028) was significantly lower in DIT than MIT. Conclusion: SBBC irradiation is more complex than unilateral breast radiotherapy. No significant difference between both techniques and OARs was observed. However, we recommend MIT as a priority technique due to the ability to protect OARs, ease of administration during treatment, and the fact that the patient stays in the treatment unit for a shorter period of time.

141 Breast-conserving therapy (BCT) in stage I–II synchronous bilateral breast cancer (SBBC)

1995 ◽  
Vol 32 ◽  
pp. 211 ◽  
Author(s):  
Smitha V. Gollamudi ◽  
Rebecca S. Gelman ◽  
Gloria Peiro ◽  
Lindsey Schneider ◽  
James L. Connolly ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bilateral Breast Cancer ◽  
Breast Conserving Therapy ◽  
Stage I ◽  
Synchronous Bilateral Breast Cancer

A CASE OF SYNCHRONOUS BILATERAL BREAST CANCER WITH DISCORDANT ESTROGEN RECEPTOR STATUS

2021 ◽  
pp. 72-73
Author(s):  
B Santhi ◽  
S Savitha ◽  
S Sujitha
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Estrogen Receptor Status ◽  
Bilateral Breast Cancer ◽  
Breast Conservation ◽  
Time Interval ◽  
Rare Entity ◽  
Synchronous Bilateral Breast Cancer ◽  
Metachronous Breast Cancer ◽  
Degree Of Differentiation

Synchronous bilateral breast cancer is dened as two tumours diagnosed within 6 month interval and those above 6 months termed as metachronous breast cancer though there is difference in time interval specied by various clinicians. SBBC is a rare entity with incidence of 0.3 – 1.2% though it is recently increasing due to improved life expectancy after treatment and routine use of contralateral mammography. It is considered that synchronous breast tumours are independent tumours than to be secondary to metastatic spread from primary. Presence of indraductal component, different histology and different degree of differentiation implies that 2 they are independent tumors. Mostly women with BSBC are treated with aggressive measures as they are thought to be aggressive. Recently overall consensus is that bilateral breast cancer is amenable to breast conservation surgeries 1 without compromising surviva

The Global Burden of Breast Cancer in Women

2019 ◽  
pp. 3-16
Author(s):  
Isabelle Soerjomataram ◽  
Claudia Allemani ◽  
Adri Voogd ◽  
Sabine Siesling
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Breast Cancer Incidence ◽  
Cancer Control ◽  
Population Based ◽  
High Income ◽  
Cancer Risk Factors ◽  
Consequent Reduction ◽  
Breast Cancer Risk Factors ◽  
Sub Saharan

Abstract: Breast cancer is the most frequently diagnosed cancer and the leading cause of death from cancer in women. The number of women diagnosed with breast cancer world-wide is projected to increase from an estimated 1.7 million per year in 2012 to 2.2 million new cases per year by 2035. The largest component of this increase relates to demographic change (increasing and ageing populations), changes in breast cancer risk factors linked to westernization, and adoption of unhealthy lifestyles. Although major successes have been observed in improving survival from breast cancer, with a consequent reduction in mortality, these gains have mainly been observed in high-income countries. The international range in population-based survival also remains wide: the most recent 5-year net survival estimates range from <60% in some regions of sub-Saharan Africa to >85% in many high-income countries. These disparities are undoubtedly linked to inadequate access to diagnostic and treatment facilities in low-resource regions, where the number of women being diagnosed each year is still increasing and breast cancer is becoming an urgent problem. Tackling the growing burden of breast cancer will require comprehensive programmes of cancer control, with primary prevention, screening, and treatment tailored to local risk factors and health system capacities. Ongoing global initiatives on breast cancer have developed resource-stratified guidelines to promote early detection and treatment that meet the local cultural and economic situation. Wider adoption and quality assurance of such programmes will be key to reducing the observed global disparities in breast cancer incidence and survival.

Determining the prognosis of women with synchronous bilateral breast cancer

2007 ◽  
Vol 33 (9) ◽  
pp. 1123-1123
Author(s):  
T IRVINE ◽  
D ALLEN ◽  
C GILLETT ◽  
I FENTIMAN ◽  
H HAMED
Keyword(s):  
Breast Cancer ◽  
Bilateral Breast Cancer ◽  
Synchronous Bilateral Breast Cancer

Trends in the diagnosis of synchronous bilateral breast cancer

2018 ◽  
Vol 44 (6) ◽  
pp. 909
Author(s):  
Yan Yu Tan ◽  
Mihir Chandarana ◽  
Frank Liaw ◽  
Sadaf Jafferbhoy ◽  
Sekhar Marla ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bilateral Breast Cancer ◽  
Synchronous Bilateral Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document